Authors
Susan A Galel, Phillip C Williamson, Michael P Busch, Danielle Stanek, Sonia Bakkour, Mars Stone, Kai Lu, Scott Jones, Susan N Rossmann, Lisa Lee Pate, cobas Zika IND Study Group
Publication date
2017/3
Journal
Transfusion
Volume
57
Issue
3pt2
Pages
762-769
Description
BACKGROUND
Zika virus (ZIKV) has spread in the Americas, including parts of the southern United States, and infection can be associated with serious complications, including congenital brain abnormalities. Probable transfusion transmission of ZIKV has been documented in Brazil.
STUDY DESIGN AND METHODS
Preemptive testing of blood donations for ZIKV RNA was implemented in southern US states at risk of local transmission using a test approved under a Food and Drug Administration (FDA) investigational new drug application, cobas Zika. Screening was expanded after issuance of an updated FDA guidance. Donations reactive on initial screening were further tested by nucleic acid and antibody tests to determine the donor status.
RESULTS
Of 358,786 donations from US states screened by individual donation testing, 23 were initially reactive on cobas Zika. Fourteen of these represented probable …
Scholar articles
SA Galel, PC Williamson, MP Busch, D Stanek… - Transfusion, 2017